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Cation exchange-high performance liquid chromatography (CE-HPLC) is increasingly being used as a ﬁrst line of investigation
for hemoglobinopathies and thalassemias. Together with a complete blood count, the CE-HPLC is eﬀective in categorizing
hemoglobinopathies as traits, homozygous disorders and compound heterozygous disorders. We carried out a one year study
in Apollo Hospitals, Chennai (Tamil Nadu, South India) during which 543 abnormal chromatogram patterns were seen. The
commonest disorder we encountered was β-thalassemia trait (37.9%), followed by HbE trait (23.2%), homozygous HbE disease
(18.9%), HbS trait (5.3%), HbE β-thalassemia (4.6%), HbS β-thalassemia (2.5%), β-thalassemia major (2.3%), HbH (1.6%),
homozygous HbS (1.4%), HbD trait (0.7%). The average value of HbA2 in β-thalassemia minor was 5.4%. β-thalassemia major
had an average HbF of 88% and in HbH the mean A2 was 1.4%. Among the HbE disorders the HbA2 + HbE was 30.1% in the
heterozygous state, 90.8% in the homozygous state and 54.8% in HbE β-thalassemia.In the sickle cell disorders, HbS varied from
30.9% in the trait to 79.9% in the homozygous state to 65.6% in HbS β-thalassemia.
1.Introduction
Hemoglobinopathies result from a structural defect in the
globin gene, whereas the thalassemias are due to a quan-
titative defect in the globin chain production. The average
frequency of HbS and HbD is 4.3% and 0.86%, respectively
in Indian population [1]. HbS, HbE, and HbD are prevalent
in India [1]. HbE gene frequency in north eastern regions
of India has been reported to be 10.9% [1]. In a study, the
prevalence of sickle cell disorders was found to vary from
2.4% to 5.6% among the tribes ofOrissa in eastern India [2].
In central India, the prevalence of sickle cell disorders was
observed to be 5.7% among children [3]. The frequency of
HbD is around 0.5–3.1% in Uttar Pradesh [4].
Hemoglobin separates into major and minor hemo-
globins when subjected to CE-HPLC. The order of elu-
tion of the various components is HbA1a, HbA1b, HbF,
LA1c/CHb-1, LA1c/CHb-2, HbA1c, P3 (Hbd component),
HbA0, and HbA2. The minor hemoglobins A1a, A1b, A1c,
F1, and the P3 component are posttranslational modiﬁ-
cations of the globin chains. HbA2, a minor hemoglobin,
however, is composed of two alpha and two delta chains.
HbA0 and HbF are the major hemoglobins in a normal
hemolysate.
An elevated HbA2 with an average value of about 5%,
along with microcytic hypochromic indices, is characteristic
ofβ-thalassemia trait[5].Inβ-thalassemia major,inaddition
to a markedly microcytic hypochromic blood picture, there
are elevatedHbA2and elevatedHbFranging from 10to 90%
[5]. HbE trait is diagnosed by the presence of a high HbA2
(E+A2), approximately 30% [6]. Homozygous HbE patients
have approximately 90% HbE+A2 with minor elevation of
HbF [6]. HbE+A2 levels of 40–60% with marked elevation
of HbF are seen in HbE-β-thalassemias [6]. HbS is around
40% in sickle cell trait, 90–95% in sickle cell anemias (which
varies inversely with HbF proportion), and less than 50%
in sickle β-thalassemias [7]. Approximately less than 50% of
abnormal hemoglobin is seen in HbD traits [7].
The present study highlights the detection of the hemo-
globinopathies and thalassemias by CE-HPLC. We under-
took this study as there is limited available data on large scale
studies of hemoglobinopathies in South India. Large studies
on the spectrum of hemoglobinopathies on the Bio-Rad
D-10 analyser have not been reported previously. This2 ISRN Hematology
Table 1: Distribution of hemoglobin disorders in adults and
children.
Disorder 12 years and less (%) More than 12 years (%)
β-thalassemia trait 4.7 35
HbE trait 3.6 19.5
Homozygous HbE 2.3 16.5
HbS trait 0.7 4.6
HbE β-thalassemia 1.8 2.7
HbS β-thalassemia 0.7 1.8
β-thalassemia major 2.3 —
study is a one-year study, carried out in Apollo Hospitals,
Chennai, a tertiary care hospital in South India, and includes
all patients who had a clinical or familial suspicion of
hemoglobinopathy and a hemoglobinopathy work up was
ordered for diagnostic purposes.
2.Materialsand Methods
All patients for whom a CE-HPLC was requested during
the period from December 2009 to November 2010 were
included in this study. Patients with a recent history of
transfusion (three months prior to sample collection) were
excluded from the study. A complete blood count (LH-750
analyzer) for red cell indices, a peripheral smear for red
blood cell morphology, and an HbH preparation for HbH
inclusions were studied for all the patients. HbH smear was
prepared by incubating equal volume of blood with new
methylene blue for two hours at 37◦C and then preparing a
smear similar to that for reticulocyte count. HbH inclusions
(“golf ball” inclusions) are seen as numerous, large pale blue
inclusions distributed evenly in the red cells. A sickling test
using the reducing agent sodium metabisulﬁte was prepared
for cases with an abnormal hemoglobin in the S window of
the chromatogram. The blood samples collected in EDTA
vacutainer were diluted and injected in to the analytical
cartridge of D-10 analyzer (Bio-Rad Laboratories, Hercules,
CA). Phosphate buﬀers of increasing strength are then
pumped in to the cartridge and the hemoglobins elute out
basedontheir ionicinteractions with thecartridge. The elute
ﬂows through the ﬂow cell of the ﬁlter photometer where
their absorbance at 415nm is recorded. A chromatogram for
each sample is obtained using the HbA2/HbF/HbA1c dual
program. A recorder pack containing the elution buﬀers,
calibrators, calibrator diluents, whole blood primer, and
sample vials are provided with each kit. The hemoglobins
fall into windows which are deﬁned by their retention times.
Hemoglobins with retention times outside the windows are
detected as unknown peaks. The reference ranges for HbA2
and HbF in our laboratory for adults are 1.8–4% and less
than 1, respectively.
3.Observations
There were ﬁve hundred and forty three abnormal chro-
matograms (see Figures 1, 2, 3, 4, 5,a n d6). Of these, 206
























Figure 1: β-thalassemia trait with HbA2 of 5.6 and HbF of 1.2%.
































Figure 2: HbE trait with HbA2 and HbE in the same window and
HbE+A2 amounting to 31.7%.
(37.9%) were β-thalassemia trait, 126 (23.2%) HbE trait,
103 (18.9%) homozygous HbE, 29 (5.3%) HbS trait, 25
(4.6%) HbE β-thalassemia, 14 (2.5%) HbS β-thalassemia,
13 (2.3%) β-thalassemia major, nine (1.6%) HbH, eight
(1.4%)homozygousHbS,four(0.7%)HbDtrait,one(0.1%)
each of homozygous HbD disorder, HbJ trait, HbLepore
trait, hereditary persistence of fetal hemoglobin, and HbSC
and HbSE disorder. Of these, 289 (53.2%) were males and
(46.7%) 254 females. Table 1 shows the distribution of the
common hemoglobin disorders among children and adults
in our study. Among our patients, 16.5% were less than
12 years and in both groups β-thalassemia trait was the
commonest abnormality.ISRN Hematology 3



















Figure 3: β-thalassemia major with elevated HbF.























Figure 4: HbE β-thalassemia with elevated HbF falling in the
LA1c/CHb-1 peak. HbE+A2 was 41.6% and HbF 35.7%.
3.1. Heterozygous Hemoglobinopathies (E, S, D Traits). The
lowestaveragehemoglobinwasseen inHbDtrait.The lowest
average MCV, MCH, and MCHC was seen in HbE trait.
The highest percentage of abnormal hemoglobin was seen in
HbD trait (Table 2) .T h es i n g l ec a s eo fJt r a i th a daP 3p e a k
of 22.5% (HbJ presents as an elevated P3 peak).
3.2. Compound Heterozygous Disorders (E β-Thalassemia and
S β-Thalassemia). The lowest average hemoglobin, MCV,
MCH, and MCHC were seen in HbE Beta-thalassemia.
The average abnormal hemoglobin was more in HbS β-
thalassemia compared to HbE β-thalassemias (65.6 versus

















Figure 5: HbH with HbA2 of 1.1%, elevated HbA1a, and an
unknown peak at 0.38 minutes.

























Figure 6: HbS β-thalassemia with elevation of HbF and HbA2.
54.8), whereas it was contrary to the amount of HbF (19.2
versus 31.3) (Table 3).
3.3. Homozygous Disorders (SS, EE). A lower average
hemoglobin was seen in HbSS, whereas the percentage of
abnormal hemoglobinwas higherin HbEE.The averageHbF
was, however, higher in HbSS (Table 4).
3.4. HbE Disorders (E Trait, EE, E β-Thalassemia). Com-
paring all the HbE disorders, it is seen that the lowest
hemoglobin as well as the highest proportion of HbF is seen
in HbE β-thalassemia (Table 5). The single case of HbSE4 ISRN Hematology
Table 2: Heterozygous hemoglobinopathies.
Disorder No. of cases Hbgm% MCV (ﬂ) MCH (pg) MCHC (g/dL) RDW% RBC × 106/cumm Abnor Hb%
E trait 126 10.3 75.5 24.2 31.7 16.1 4.3 30.1
S trait 29 11.3 77.2 25.1 32.3 15.6 4.5 30.9
D trait 4 10 82.6 27.3 33 17.2 3.6 35.4
Table 3: Compound heterozygous disorders.
Disorder No. of cases Hb (gm%) MCV (ﬂ) MCH (pg) MCHC (gm/dL) RDW (%) RBC × 106 cumm %Abnor Hb HbF (%)
E β-thalassemia 25 6.9 67.2 19.7 29.2 26.6 3.6 54.8 31.3
S β-thalassemia 14 9 73.8 22.8 30.7 18.9 4.1 65.6 19.2
Table 4: Homozygous hemoglobinopathies.
Disorder No. of cases Hb (gm%) MCV (ﬂ) MCH (pg) MCHC (gm/dL) RDW (%) RBC × 106 cumm Abnormal Hb %HbF
HbEE 103 9.8 63.6 20.4 31.9 18 4.8 90.8 3.7
HbSS 8 7.8 77.4 24.5 31.5 24.8 3.3 79.9 8
Table 5: HbE disorders.
Disorder No. of cases Hb (gm%) MCV (fL) MCH (pg) MCHC (gm/dL) RDW (%) RBC × 106 cumm Abnormal Hb % %HbF
HbE trait 126 10.3 75.5 24.2 31.7 16.1 4.3 30.1 1.32
HbEE 103 9.8 63.6 20.4 31.9 18 4.8 90.8 3.7
HbE β-thalassemia 25 6.9 67.2 19.7 29.2 26.6 3.6 54.8 31.3
disorder had a hemoglobin of 10.1gm%, thalassemic indices
with MCV of 71ﬂ, MCH of 23.1pg, 36.7% of HbA2+HbE,
and 2.8% of HbF.
3.5. Sickle Cell Disorders (S Trait, SS, S β-Thalassemia).
Unlike the HbE disorders, homozygous HbS disorder had
the lowest hemoglobin (Table 6) .T h es i n g l ec a s eo fH b S C
disorder had a hemoglobin of 13.8gm% and 47.1% HbS,
whereas HbS was 53.4% in HbSE disorder. The patients’
HbCeluted in the C window at 4.79 minutes and constituted
45.8% of the total hemoglobin. These values of HbS are
higher than seen in HbS trait where the average was 30.9%.
The highest average HbA2 of 4.2% was seen in HbS β-
thalassemias (Table 7).
3.6.Thalassemias (β-Thalassemia Trait,β-Thalassemia Major,
α-Thalassemia). On comparing the thalassemic disorders
in our study (β-thalassemia trait, β-thalassemia major,
and α-thalassemias), we observed that the lowest average
hemoglobin was seen in β-thalassemia major. The lowest
average MCV was seen, however, in β-thalassemia trait,
whereas the lowest average MCH and MCHC was recorded
in α-thalassemias (Table 8). The average HbF was 88% in
β-thalassemia major and less than one in α-thalassemias
(HbH).
All the cases of α-thalassemias included in our study
had numerous HbH inclusions. The single case of HbLe-
pore trait had a hemoglobin of 6.6gm%, MCV of 52.9ﬂ,
MCH of 15.8pg, an elevated HbF of 13.7%, and elevated
HbA2 of 10.6%. One case of hereditary persistence of fetal
hemoglobin was noted with a hemoglobin of 13.3gm%,
normal red cell indices, and an HbF of 36.2%.
3.7. Minor Hemoglobins (Tables 9, 10,a n d11). The highest
mean HbA1a was seen in α-thalassemias and the lowest
was noted in HbD trait. HbE β-thalassemia had the highest
mean HbA1b and the lowest was seen in homozygous HbE
disorder. HbA2 was noted to be highest in β-thalassemia
trait, and lowest in α-thalassemias (excluding the HbE
disorders where HbE and HbA2 fall in the same window and
A2 is not detected separately).
3.8. Retention Times. All our cases of HbH in addition to
having a high HbA1a with a characteristic retention time
of 0.16 minutes also had an unknown peak eluting at 0.37–
0.38 minutes. The average retention time of HbA1a was 0.21
(range from 0.19 to 0.25, except in α-thalassemias where it
was 0.16 minutes). The average retention time of HbA1b
was 0.28 with a range from 0.25 to 0.35, and HbA1c average
was 0.79, with a range of 0.71–0.97 minutes. The retention
time of HbF was 0.43, ranging from 0.41 to 0.51 in all cases
where HbF was normal or minimally elevated. In HbE β-
thalassemias, the average for HbF was 0.54 minutes, whereas
inHbSβ-thalassemias itwas 0.51.Theaverageretentiontime
of P3 peak was 1.45, with a range from 1.41 to 1.51 with the
exception of the HbJ trait where it was 1.33 minutes. HbA2
retention time ranged from 2.74 to 3.09 with an average
of 2.94. The average retention time of HbA2 in the HbE
disorderswas2.76,2.7,and 2.71inHbEtrait,HbEEdisorder,
and HbE β-thalassemia, respectively. The retention time forISRN Hematology 5
Table 6: HbS disorders.
Disoder No. of cases Hb (gm%) MCV (ﬂ) MCH (pg) MCHC (gm/dL) RDW (%) RBC × 106 cumm Abnormal Hb % %HbF
HbS trait 29 11.3 77.2 25.1 32.3 15.6 4.5 30.9 1.34
HbSS 8 7.8 77.4 24.5 31.5 24.8 3.3 79.9 8
HbS β-thalassemia 14 9 73.8 22.8 30.7 18.9 4.1 65.6 19.2
Table 7: HbA2 in sickle cell disorders.




HbS ranged from 4.04 to 4.18 in HbS trait with an average of
4.13. In HbSS disorder, the average was 4.08 and it was 4.10
in HbS β-thalassemias. HbD had an average retention time
of 3.75 with a range from 3.72 to 3.82. In homozygous HbD,




(37.9%), followed by HbE trait (23.2%), homozygous HbE
(18.9%), HbS trait (5.3%), HbE β-thalassemia (4.6%), HbS
β-thalassemia (2.5%), β-thalassemia major (2.3%), HbH
(1.6%), homozygous HbS (1.4%), and HbD trait (0.7%).
This compares with other studies [8, 9]( Table 12)w h e r e
β-thalassemia trait is the commonest disorder. In the study
by Balgir [10], sickle cell trait was noted to be common
as the study included tribes from Orissa where this gene is
prevalent.Ourstudy had a high proportionofHbEdisorders
due to the many patients from north eastern regions of India
who frequent our hospital for treatment.
The average value of HbA2 was 5.4% in β-thalassemia
traits compared to 5% in other studies [5]. HbF was
minimally elevatedin 42%ofourβ-thalassemia traitpatients
and was around 1.4%. HbF ranges from 10 to 90% in β-
thalassemia major [5]. In our study, the HbF average was
88%. HbA2 may be elevated in β-thalassemia major and in
ourstudy 15% ofthe patientswith β-thalassemia major were
seen to have elevated HbA2 and the average value of HbA2
was around 3.1%.
In the Bio-Rad Variant analyser, HbH can only be
suspected by the presence of peaks at the beginning of the
chromatogram. In the D-10 analyser, we have seen that
in addition to an elevation of HbA1a with a characteristic
retention time of 0.16 there was an unknown peak at 0.37–
0.38 minutes. All our cases of HbH had low HbA2 with an
average of 1.4%, and numerous HbH inclusions.
HbE+A2 has been reported to be around 30% in HbE
trait [6]. In our study, the average was 30.1% with a minimal
elevation of HbF of 1.32%. HbE+A2 has been reported to be
around 90% with minimal elevation of HbF in homozygous
HbE, and it is about 40–60% in HbE β-thalassemias [6].
In our study, HbE+A2 was 90.8% in homozygous HbE and
54.8%in HbEβ-thalassemias. HbFwas 3.7%in homozygous
HbE and 31.3% in HbE β-thalassemias.
HbS has been reported to be around 40% in trait,
90–95% in homozygous HbS, and less than 50% in HbS
β-thalassemias [7]. In our cases, it was 30.9% in trait,
79.9% in the homozygous forms, and 65.6% in HbS β-
thalassemia. On comparing HbE β-thalassemia and HbS
β-thalassemia disorders, it is seen that the percentage of
abnormal hemoglobin was more in HbS β-thalassemia than
HbE β-thalassemias and the converse was seen for HbF
(31.3 in E disorder and 19.2 in S disorder). However,
the homozygous disorders of the same showed a higher
abnormal hemoglobin in homozygous HbE (90.8%) with a
lower average HbF (3.7%) when compared to homozygous
HbS where it was 79.9% and 8%, respectively. The lowest
average hemoglobin among these four disorders was seen in
homozygous HbS (7.8%). The reason for this could be that
the sickle cell disorders are hemolytic disorders, whereas the
HbE disorders are somewhat similar to thalassemic disorders
(due to slower production), and hence in the homozygous
form HbS is noted to have the lowest hemoglobin. It is
interesting to note that among the HbE disorders HbE β-
thalassemia had the lowest hemoglobin and also the highest
proportion of HbF. This does not reﬂect the clinical diversity
of this disorder where highest HbF is noted in patients with
a higher hemoglobin level. In all our cases of HbE disorders,
the levels of HbA2 could not be evaluated as the presence of
HbE is suspected by the presence ofa abnormally high HbA2
peak. HbLepore, HbD-Iran, and others such as HbHonolulu
also present as a raised HbA2 peak and the ethnicity along
with the amount of abnormal hemoglobin is taken in to
account before labeling these patients. HbLepore has been
reported to have a characteristic hump in the HbA2 peak.
However, in our patient it was not seen and the HbA2 was
elevated to 10.6%. The level of HbD has been reported to
be less than 50% in traits, and in our cases the average was
35.4%.
Levels of all the minor hemoglobins have not been
reported in previous studies. Maximal elevation of minor
hemoglobin HbA1a (7.6) was seen in HbH and of HbA1b
(6.5) was seen in HbE β-thalassemia. The signiﬁcance of
this is not known. The retention times on the D-10 analyser
have not been reported previously and to the best of our
knowledge this is the ﬁrst study detailing the retention times.
After a detailed search, we have found only one large-scale
study on the D-10 analyser [11], and to the best of our
knowledge this is the ﬁrst report from South India.
In addition to HbA2 being unrecordable in HbE disor-
ders, the other drawback is the inability to measure HbA1c6 ISRN Hematology
Table 8: Comparison of thalassemias(—indicates not detected).
Disorder No. of cases Hb (gm%) MCV (ﬂ) MCH (pg) MCHC (gm/dL) RDW (%) RBC × 106 cumm Hb F% Hb A%
β thal trait 206 10.4 65.5 19.9 30.5 16.5 5.2 1.4 81.3
β thal major 13 4.8 67.9 21.1 31 30.9 2.4 88 7.2
α thal 9 8.3 67.2 18.4 28.2 23.3 4.5 — 77.4
Table 9: Minor hemoglobins in homozygous and compound
heterozygous disorders (—indicates not detected).
Disorder A1a A1b A1c A2
Hb SS 1.7 — 4.6 2.7
Hb EE 1.1 0.2 3.2 90.8
Hb S β thal 3.4 3.8 5.5 4.2
Hb E β thal 3.5 6.5 5.1 54.8
Table 10: Minor hemoglobins in heterozygous disorders.
Disorder A1a A1b A1c A2
Hb S trait 0.9 1.03 5.4 3.3
Hb E trait 1.2 0.84 5.1 30.1
Hb D trait 0.3 0.97 4.6 3.12
Table 11: Thalassemias and minor hemoglobins (—indicates not
detected).
Disorder A1a A1b A1c A2
β thal trait 1.13 1.3 5.5 5.4
β thal major — — — 3.1
α thal (HbH) 7.6 0.8 3.3 1.4
Table 12: Comparisonwith other studies.






β thal trait 37.9 8.9 18.1 18.2
HbE trait 23.2 0.19 1.1 0.9
HbS trait 5.3 — 1.4 29.8
E β-thalassemia 4.6 0.23 1.3 0.7
S β-thalassemia 2.5 0.07 0.8 1.7
Hb SS 1.4 0.03 0.5 7.5
β-thalassemia major 2.3 0.6 2.9 5.3
in presence ofhigh HbFlevels(15% and more). The elevated
HbF then presents as an elevated HbA1c or elevated LA1c
(thelabileportionofA1c)andothermethodshavebetoused
to evaluate the same.
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